Evaluation of the Applicability of External X-ray Radiation to Stimulate the Autoradiolysis Processes in Therapeutic Radiopharmaceuticals (Exemplified by [153Sm]Sm-PSMA-617 and [177Lu]Lu-PSMA-617)

Yu. A. Mitrofanov; Митрофанов Ю. А.; V. B. Bubenshchikov; Бубенщиков В. Б.; A. V. Belousov; Белоусов А. В.; A. S. Lunev; Лунёв А. С.; A. A. Larenkov; Ларенков А. А.

doi:10.31857/S0023119323010096

Evaluation of the Applicability of External X-ray Radiation to Stimulate the Autoradiolysis Processes in Therapeutic Radiopharmaceuticals (Exemplified by [153Sm]Sm-PSMA-617 and [177Lu]Lu-PSMA-617)

Authors: Mitrofanov Y.A.¹, Bubenshchikov V.B.¹, Belousov A.V.¹, Lunev A.S.¹, Larenkov A.A.¹
Affiliations:
1. State Research Center—Burnasyan Federal Medical Biophysical Center of Federal Medical Biological Agency
Issue: Vol 57, No 1 (2023)
Pages: 28-38
Section: RADIATION CHEMISTRY
URL: https://kld-journal.fedlab.ru/0023-1193/article/view/661529
DOI: https://doi.org/10.31857/S0023119323010096
EDN: https://elibrary.ru/DCWVPG
ID: 661529

Cite item

Full Text

Open Access
Restricted Access

Access granted
Restricted Access

Subscription Access

Abstract
About the authors
References
Supplementary files
Statistics

Abstract

The paper presents the results of a study on the radiolytic degradation of vector molecules in radiopharmaceuticals, caused by ionizing radiation from the radionuclide used in the preparations, in comparison with the equal dose of external X-ray irradiation. The dose factors for therapeutic radionuclides samarium-153 and lutetium-177 in aqueous solutions were estimated in geometry simulating the finished dosage form of radiopharmaceuticals (standard injection vial ) both by computational methods (in silico) and applying chemical dosimetry. Irradiation with external X-ray source to doses formed in volume of therapeutic radiopharmaceuticals with given radioactivity concentration was performed on an LNK-268 X-ray unit. Using the [153Sm]Sm-PSMA-617 and [177Lu]Lu-PSMA-617 radiopharmaceuticals as an instance, we compared the degree of radiolytic degradation and the profiles of radiolytic impurities formed as a result of both external X-ray irradiation and autoradiolysis. Qualitative coincidence of the impurity profiles formed in both cases was noted. It has been shown that external X-ray radiation can be used to simulate the autoradiolysis processes of radiopharmaceuticals if additional corrections are made for the type of radiation and dose rate.

Keywords

dosimetry, radiolysis, radiopharmaceutical, 177Lu, 153Sm, PSMA-617, simulation, radiochemical purity

References

Dolgin E. // Nat. Biotechnol. 2018. V. 36. № 12. P. 1125–1127. https://doi.org/10.1038/nbt1218-1125
Hennrich U., Kopka K. // Pharmaceuticals. 2019. V. 12. № 3. P. 114. https://doi.org/10.3390/ph12030114
Novartis PluvictoTM approved by FDA as first targeted radioligand therapy for treatment of progressive, PSMA positive metastatic castration-resistant prostate cancer | Novartis [Electronic resource]. URL: https://www.novartis.com/news/media-releases/novartis-pluvictotm-approved-fda-first-targeted-radioligand-therapy-treatment-progressive-psma-positive-metastatic-castration-resistant-prostate-cancer (accessed: 01.08.2022).
Baudhuin H., Cousaert J., Vanwolleghem P., Raes G., Caveliers V., Keyaerts M., Lahoutte T., Xavier C. // Pharmaceuticals. 2021. V. 14. № 5. P. 448 https://doi.org/10.3390/ph14050448
Mu L., Hesselmann R., Oezdemir U., Bertschi L., Blanc A., Dragic M., Löffler D., Smuda C., Johayem A., Schibli R. // Appl. Radiat. Isot. 2013. V. 76. P. 63–69 https://doi.org/10.1016/j.apradiso.2012.07.022
Martin S., Tönnesmann R., Hierlmeier I., Maus S., Rosar F., Ruf J., Holland J.P., Ezziddin S., Bartholomä M.D. // J. Med. Chem. 2021. V. 64. № 8. P. 4960–4971 https://doi.org/10.1021/acs.jmedchem.1c00045
Rothschild W.G., Allen A.O. // Radiat. Res. 1958. V. 8. № 2. P. 101. https://doi.org/10.2307/3570600
Hart E.J., Walsh P.D. // Radiat. Res. 1954. V. 1. № 4. P. 342–346.
Hart E.J. // Radiat. Res. 1955. V. 2. № 1. P. 33–46.
Bjergbakke E., Sehested K. // Radiation Chemistry / ed. Hart E.J. 1968. P. 579–584. https://doi.org/10.1021/ba-1968-0081.ch040
Sharpe P.H.G., Barrett J.H., Berkley A.M. // Int. J. Appl. Radiat. Isot. 1985. V. 36. № 8. P. 647–652. https://doi.org/10.1016/0020-708X(85)90006-7
Sharpe P.H.G., Sehested K. // Int. J. Radiat. Appl. Instrumentation. Part C. Radiat. Phys. Chem. 1989. V. 34. № 5. P. 763–768. https://doi.org/10.1016/1359-0197(89)90281-6
Sharpe P., Miller A., Bjergbakke E. // Int. J. Radiat. Appl. Instrumentation. Part C. Radiat. Phys. Chem. 1990. V. 35. № 4–6. P. 757–761. https://doi.org/10.1016/1359-0197(90)90311-5
Wang F., Li Z., Feng X., Yang D., Lin M. // Prostate Cancer Prostatic Dis. Springer US, 2022. V. 25. № 1. P. 11–26. https://doi.org/10.1038/s41391-021-00394-5
Kopka K., Benešová M., Bařinka C., Haberkorn U., Babich J. // J. Nucl. Med. 2017. V. 58. № Supplement 2. P. 17S–26S. https://doi.org/10.2967/jnumed.116.186775
Allison J., Amako K., Apostolakis J., Arce P., Asai M., Aso T., Bagli E., Bagulya A., Banerjee S., Barrand G., Beck B.R., Bogdanov A.G., Brandt D., Brown J.M.C., Burkhardt H., Canal P., Cano-Ott D., Chauvie S., Cho K., et al. // Nucl. Instruments Methods Phys. Res. Sect. A Accel. Spectrometers, Detect. Assoc. Equip. 2016. V. 835. P. 186–225. https://doi.org/10.1016/j.nima.2016.06.125
Taschereau R., Chow P.L., Cho J.S., Chatziioannou A.F. // Nucl. Instruments Methods Phys. Res. Sect. A Accel. Spectrometers, Detect. Assoc. Equip. 2006. V. 569. № 2 SPEC. ISS. P. 373–377. https://doi.org/10.1016/j.nima.2006.08.038
Khusnulina A. // IOP Conf. Ser. Mater. Sci. Eng. 2014. V. 66. № 1. P. 012032. https://doi.org/10.1088/1757-899X/66/1/012032
Stabin M.G., Konijnenberg M.W. // J. Nucl. Med. 2000. V. 41. № 1. P. 149–160.
Radionuclide Decay Data [Electronic resource]. URL: http://hps.org/publicinformation/radardecaydata.cfm (accessed: 15.05.2022).
Andersson M., Johansson L., Eckerman K., Mattsson S. // EJNMMI Res. EJNMMI Research, 2017. V. 7. № 1. P. 88. https://doi.org/10.1186/s13550-017-0339-3
Goorley T., James M., Booth T., Brown F., Bull J., Cox L.J., Durkee J., Elson J., Fensin M., Forster R.A., Hendricks J., Hughes H.G., Johns R., Kiedrowski B., Martz R., Mashnik S., McKinney G., Pelowitz D., Prael R., et al. // Nucl. Technol. 2012. V. 180. № 3. P. 298–315. https://doi.org/10.13182/NT11-135
de Blois E., Chan H.S., de Zanger R., Konijnenberg M., Breeman W.A.P. // Appl. Radiat. Isot. Elsevier, 2014. V. 85. P. 28–33. https://doi.org/10.1016/j.apradiso.2013.10.023
de Blois E., Sze Chan H., Konijnenberg M., de Zanger R., A.P. Breeman W. // Curr. Top. Med. Chem. 2013. V. 12. № 23. P. 2677–2685. https://doi.org/10.2174/1568026611212230005
Ruigrok E.A.M., Tamborino G., de Blois E., Roobol S.J., Verkaik N., De Saint-Hubert M., Konijnenberg M.W., van Weerden W.M., de Jong M., Nonnekens J. // Eur. J. Nucl. Med. Mol. Imaging. Springer Berlin Heidelberg, 2022. № 0123456789. P. https://doi.org/10.1007/s00259-022-05821-w
Traino A.C., Marcatili S., Avigo C., Sollini M., Erba P.A., Mariani G. // Med. Phys. 2013. V. 40. № 4. P. 042505. https://doi.org/10.1118/1.4794473
PRODUCT MONOGRAPH LUTATHERA ® [Electronic resource] // Toxicology. 2010. P. 1–55. URL: https://www.samnordic.se/wp-content/uploads/ 2018/05/LUTATHERA-MONOGRAPH-120218.pdf.
Dosing & Administration I PLUVICTO [Electronic resource]. URL: https://www.hcp.novartis.com/products/pluvicto/psma-positive-mcrpc/dosing-and-administration/ (accessed: 01.08.2022).
LnHB. Nuclear data – Laboratoire National Henri Becquerel [Electronic resource]. URL: http://www.lnhb.fr/nuclear-data/nuclear-data-table/ (accessed: 14.08.2022).
de Zanger R.M.S., Chan H.S., Breeman W.A.P., de Blois E. // J. Radioanal. Nucl. Chem. Springer International Publishing, 2019. V. 321. № 1. P. 285–291. https://doi.org/10.1007/s10967-019-06573-y